Oxford BioDynamics PLC has announced a partnership with The London Clinic, a leading private hospital in the UK, to provide access to the company's EpiSwitch PSE and CiRT blood tests. The London Clinic, located in London's renowned medical district at Harley Street, will integrate these tests into its suite of oncology diagnostics, aligning with the opening of its state-of-the-art Rapid Diagnostics Centre. The EpiSwitch PSE test, which significantly enhances the predictive accuracy of standard PSA tests for prostate cancer, will be available to patients. The EpiSwitch CiRT test, designed to identify patients who will respond to Immune Checkpoint Inhibitor therapy, will also be accessible to doctors at The London Clinic.

Dr. Rowan Miller, Clinical Director for Oncology at The London Clinic, emphasized the importance of accurate and early cancer diagnosis, stating, "The qualities of OBD's accurate PSE and CiRT tests align with our commitment to providing cutting-edge innovation and excellence in personalized patient care." The EpiSwitch PSE test, with a 94% predictive accuracy, high specificity, sensitivity, and positive and negative predictive values, has been developed through collaborative work and published in a peer-reviewed publication. The EpiSwitch CiRT test, on the other hand, provides a binary result to support treatment planning for Immune Checkpoint Inhibitor therapy.

Dr. Jon Burrows, Chief Executive Officer of Oxford BioDynamics, highlighted the need for more accurate, minimally-invasive blood tests for detecting prostate cancer and predicting response to immunotherapy. He expressed that the partnership with The London Clinic will enhance access to these potentially life-changing blood tests in the heart of London. This collaboration follows a previous joint announcement with Bupa UK to provide coverage for the EpiSwitch CiRT test, further expanding the availability of these tests.

The partnership between Oxford BioDynamics and The London Clinic represents a significant step in providing advanced diagnostic tools to aid in the early detection and treatment planning for cancer patients. The integration of EpiSwitch PSE and CiRT tests into The London Clinic's oncology toolbox reflects a commitment to leveraging innovative technologies to improve patient care and outcomes.